The Company is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications and TYME-18 for the treatment of solid tumors.
PRNewswire/ - Ademi LLP is investigating TYME (NASDAQ:TYME) for possible breaches of fiduciary duty and other violations of law in its transaction with. Looking at the last year, the company burnt through US21m. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of. When Tyme Technologies last reported its balance sheet in September 2021, it had zero debt and cash worth US76m. has obtained a Fair Price in its transaction with Syros PR Newswire - Tue Jul 5, 10:20AM CDT. Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. Tyme is one of the world’s fastest-growing digital banking groups, building high-tech and high-touch banks in fast-growing, emerging markets. Taking a look at stock we notice that its last check on previous day was 0.30 and 5Y monthly beta was reading 1.07 with its price kept floating in the range of 0.287 and 0.3047 on the day. Its preclinical pipeline programs SM-88i, TYME-18, TYME-T and TYME-19. SYRS : 0.9350 (+9.36) Shareholder Alert: Ademi LLP investigates whether TYME Technologies, Inc. (NASDAQ:TYME) concluded the trading at 0.30 on Friday, July 22 with a rise of 0.33 from its closing price on previous day. TYME is focused on evaluating its preclinical pipeline of novel CMBT programs, and TYME-19 as a potential therapeutic for SARS CoV-2 diseases. TYME's lead drug product, SM-88, is an oral investigational modified proprietary tyrosine derivative that interrupt the metabolic processes of cancer cells by breaking down the cells key defenses and leading to cell death through oxidative st ress and exposure to the body's natural immune system. (TYME) is a biotechnology company focused on developing cancer metabolism-based therapies for a solid tumors and hematologic cancers.